“Authors’ Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn’s disease: what are the reasons for differences from previous studies?”, Clinics, vol. 74, p. e1517, Oct. 2019, doi: 10.6061/clinics/2019/e1517.